Abstract
AbstractHerein, twenty‐six benzoylthioureas were evaluated for their antimicrobial activity against different bacterial and fungal species. Two 4‐substituted benzoylthiourea, one benzoylurea and one benzoylguanidine derivatives were further synthesized to identify the most promising compound. Eight compounds were active against at least one microbial species tested. N‐(butylcarbamothioyl)‐benzamide (1 e) exhibited the best antimicrobial activity towards Streptococcus agalactiae (group B Streptococcus‐GBS), including clinical isolates susceptible or resistant to clindamycin and/or erythromycin and azithromycin. 1 e presented a bacteriostatic effect, causing morphological and ultrastructural alterations on planktonic cells, and decreased the metabolic activity of GBS biofilms. No hemolytic and cytotoxicity to mammalian cells were detected for 1 e, that also displayed drug‐likeness properties. Molecular docking was performed on Streptococcus pneumoniae enoyl‐ACP reductase obtained by homology modeling. 1 e showed relevant interactions with the GBS enoyl‐ACP reductase enzyme. N‐(butylcarbamothioyl)‐benzamide may be a good starting point for the development of new antimicrobials against GBS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.